Page last updated: 2024-10-25

citalopram and Diseases, Metabolic

citalopram has been researched along with Diseases, Metabolic in 3 studies

Citalopram: A furancarbonitrile that is one of the serotonin uptake inhibitors used as an antidepressant. The drug is also effective in reducing ethanol uptake in alcoholics and is used in depressed patients who also suffer from TARDIVE DYSKINESIA in preference to tricyclic antidepressants, which aggravate dyskinesia.
citalopram : A racemate comprising equimolar amounts of (R)-citalopram and its enantiomer, escitalopram. It is used as an antidepressant, although only escitalopram is active.
1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile : A nitrile that is 1,3-dihydro-2-benzofuran-5-carbonitrile in which one of the hydrogens at position 1 is replaced by a p-fluorophenyl group, while the other is replaced by a 3-(dimethylamino)propyl group.

Research Excerpts

ExcerptRelevanceReference

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (33.33)29.6817
2010's2 (66.67)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Zemdegs, J1
Quesseveur, G1
Jarriault, D1
PĂ©nicaud, L1
Fioramonti, X1
Guiard, BP1
Kamarck, TW1
Muldoon, MF1
Manuck, SB1
Haskett, RF1
Cheong, J1
Flory, JD1
Vella, E1
Atar, D1
Malinin, A1
Pokov, A1
van Zyl, L1
Frasure-Smith, N1
Lesperance, F1
Serebruany, VL1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
[NCT00217828]0 participants Interventional2002-03-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trials

1 trial available for citalopram and Diseases, Metabolic

ArticleYear
Citalopram improves metabolic risk factors among high hostile adults: results of a placebo-controlled intervention.
    Psychoneuroendocrinology, 2011, Volume: 36, Issue:7

    Topics: Adult; Aggression; Algorithms; Antidepressive Agents; Citalopram; Female; Health Behavior; Hostility

2011

Other Studies

2 other studies available for citalopram and Diseases, Metabolic

ArticleYear
High-fat diet-induced metabolic disorders impairs 5-HT function and anxiety-like behavior in mice.
    British journal of pharmacology, 2016, Volume: 173, Issue:13

    Topics: Animals; Anxiety; Behavior, Animal; Citalopram; Diet, High-Fat; Male; Metabolic Diseases; Mice; Mice

2016
Antiplatelet properties of escitalopram in patients with the metabolic syndrome: a dose-ranging in vitro study.
    Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2007, Volume: 32, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Biomarkers; Citalopram; Dose-Response Relation

2007